Physician profile
Michael Carelli
NPI 1497708515
$3,473.41
in general payments reported to CMS, 2019-2025
25 companies · $516 in 2025
The $516 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $485 · 2021: $912 · 2022: $614 · 2023: $185 · 2024: $212 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $443.70 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $319.81 | 2020-2021 | |
| Abbvie INC. | $309.51 | 2022-2024 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $305.27 | 2020-2025 | Precision7 |
| Glaukos Corporation | $255.28 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $247.12 | 2020-2021 | |
| Coopervision INC. | $228.78 | 2021-2025 | Clariti Contact Lens |
| Dompe US, INC. | $191.46 | 2021-2024 | Oxervate |
| Optovue, INC. | $171.09 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $131.39 | 2024-2025 | |
| Amgen INC. | $121.92 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $117.67 | 2022-2023 | Tecnis Iol |
| Allergan, INC. | $104.53 | 2020-2021 | |
| Oyster Point Pharma, INC. | $88.49 | 2022-2025 | Ryzumvi, Tyrvaya |
| Sight Sciences, INC. | $82.72 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hoffmann-La Roche Limited | $79.54 | 2019 | |
| Harrow Eye, LLC | $76.30 | 2025 | Vevye |
| Visionix USA, INC | $74.99 | 2022 | |
| Aerie Pharmaceuticals, INC. | $26.54 | 2021 | |
| Omeros Corporation | $19.47 | 2021 | |
| Rxsight INC | $17.30 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Eyepoint US, INC. | $17.04 | 2019 | |
| Bausch & Lomb Americas INC. | $14.73 | 2025 | Miebo, Xiidra |
| Shire North American Group INC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.